Search Results - "Knight, Beverly"

Vectorial Transport of Fexofenadine across Caco-2 Cells: Involvement of Apical Uptake and Basolateral Efflux Transporters by Ming, Xin, Knight, Beverly M, Thakker, Dhiren R

“…Fexofenadine is a nonsedative antihistamine that exhibits good oral bioavailability despite its zwitterionic chemical structure and efflux by P-gp. Evidence…”
Get full text

Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia by Garrett, May, Knight, Beverly, Cortes, Jorge E, Deininger, Michael W

“…The BELA and BFORE trials compared bosutinib starting doses of 500 mg once daily (QD) and 400 mg QD, respectively, with imatinib in adults with newly diagnosed…”
Get full text

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans by Fourie, Anne M., Cheng, Xiaoli, Chang, Leon, Greving, Carrie, Li, Xinyi, Knight, Beverly, Polidori, David, Patrick, Aaron, Bains, Trpta, Steele, Ruth, Allen, Samantha J., Patch, Raymond J., Sun, Chengzao, Somani, Sandeep, Bhandari, Ashok, Liu, David, Huie, Keith, Li, Shu, Rodriguez, Michael A., Xue, Xiaohua, Kannan, Arun, Kosoglou, Teddy, Sherlock, Jonathan P., Towne, Jennifer, Holland, M. Claire, Modi, Nishit B.

“…The interleukin (IL)-23 pathway is a pathogenic driver in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Currently, no oral therapeutics…”
Get full text

P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism by Dufek, Matthew B, Knight, Beverly M, Bridges, Arlene S, Thakker, Dhiren R

“…P-glycoprotein (P-gp) and CYP3A (cytochrome P450 3A, generally; Cyp3a, rodent enzyme) in the intestine can attenuate absorption of orally administered drugs…”
Get full text

Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia by Hibma, Jennifer, Knight, Beverly

“…Background and Objective Gemtuzumab ozogamicin is an antibody–drug conjugate composed of the anti-CD33 monoclonal antibody hP67.6 covalently linked to N…”
Get full text

A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers by Knight, Beverly, Rassam, Danielle, Liao, Shanmei, Ewesuedo, Reginald

“…Purpose This study compared the pharmacokinetics of PF-06439535, a potential bevacizumab biosimilar, to bevacizumab sourced from the European Union…”
Get full text

Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia by Masters, Joanna C., Barry, Elly, Knight, Beverly

“…Background and Objective To date, the population pharmacokinetics (popPK) of gemtuzumab ozogamicin (GO), a CD33-directed antibody–drug conjugate consisting of…”
Get full text

Su1738 JNJ-77242113, AN ORAL PEPTIDE SELECTIVELY TARGETING THE IL-23 RECEPTOR, DEMONSTRATES PHARMACODYNAMIC ACTIVITY IN RAT AND HUMAN COLON TISSUE EXPLANTS FOLLOWING ORAL DOSING by de Leon-Tabaldo, Aimee, Strawn, David, Chang, Leon, Cheng, Xiaoli, Greving, Carrie, Knight, Beverly, Sendecki, Jocelyn, Sherlock, Jonathan, Modi, Nishit B., Kannan, Arun K., Fourie, Anne M.

Get full text

About the Artist: Greg Semu by KNIGHT, BEVERLY

“…Independent indigenous researcher, curator, and artist Greg Semu was born in Aotearoa/New Zealand in 1971. He embraces Samoa as his ancestral and spiritual…”
Get full text

About the Artist: Greg Semu by Knight, Beverly

“…Introduces the Sydney based NZ-Samoan artist. Describes his artistic practices, including his 'Body on the Line' exhibition which featured photographs of…”
Get full text

Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia by Garrett, May, Knight, Beverly, Cortes, Jorge E., Deininger, Michael W.

“…Introduction: Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor that has demonstrated efficacy and a manageable safety profile in adult…”
Get full text

S1028 Characterization of a First-in-Class Oral Therapy Selectively Targeting the IL-23 Pathway by Fourie, Anne, Cheng, Xiaoli, Chang, Leon, Greving, Carrie, Patrick, Aaron, Knight, Beverly, Polidori, David, Patch, Raymond, Bhandari, Ashok, Liu, David, Huie, Keith, Li, Shu, Rodriguez, Michael, Kannan, Arun, Sherlock, Jonathan, Modi, Nishit

Get full text

Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase by Smith, Christopher R., Dougan, Douglas R., Komandla, Mallareddy, Kanouni, Toufike, Knight, Beverly, Lawson, J. David, Sabat, Mark, Taylor, Ewan R., Vu, Phong, Wyrick, Corey

“…The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton’s tyrosine kinase are reported. A fragment-based screening…”
Get full text

Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)‑5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro‑3H‑1,2,4-triazol-3-one, by Fragment-Based Drug Design by Sabat, Mark, Dougan, Douglas R, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

“…This publication details the successful use of FBDD (fragment-based drug discovery) principles in the invention of a novel covalent Bruton’s tyrosine kinase…”
Get full text

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-triazol-3-one, by Fragment-Based Drug Design” by Sabat, Mark, Dougan, Douglas R, Ermolieff, Jacques, Halkowycz, Petro, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Get full text

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)‑5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro‑3H‑1,2,4-triazol-3-one, by Fragment-Based Drug Design” by Sabat, Mark, Dougan, Douglas R, Ermolieff, Jacques, Halkowycz, Petro, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Get full text

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-triazol-3-one, by Fragment-Based Drug Design by Sabat, Mark, Dougan, Douglas R, Knight, Beverly, Lawson, J David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

“…This publication details the successful use of FBDD (fragment-based drug discovery) principles in the invention of a novel covalent Bruton's tyrosine kinase…”
Get full text

Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge by Knight, Beverly, Troutman, Matthew, Thakker, Dhiren R

“…Metabolism by cytochrome P4503A (CYP3A) and P-glycoprotein (P-gp)-mediated efflux are two important biochemical barriers to drug absorption from the intestine…”
Get full text

Interplay between p-glycoprotein-mediated efflux and cytochrome P4503A-mediated metabolism in the intestine by Knight, Beverly M

“…Intestinal metabolism and drug efflux are recognized as two important barriers to drug absorption. The interactions between these factors may also be an…”
Get full text

Interplay between p-glycoprotein-mediated efflux and cytochrome P4503A-mediated metabolism in the intestine by Knight, Beverly M

“…Intestinal metabolism and drug efflux are recognized as two important barriers to drug absorption. The interactions between these factors may also be an…”
Get full text